CCL2 and melanoma: Another innovative nanoformulation was applied to combat angiogenesis in the melanoma model: IL-13-conjugated long-circulating liposomes, loaded with the chemotherapy drug simvaststin (IL-13-LCL-SIM) and PEG-coated extracellular vesicles derived from melanoma cells and loaded by doxorubicin (PEG-EV-DOX), were used in combination and demonstrated effective targeting both to TAMs and melanoma cells and strong suppression of a number of pro-angiogenic factors (VEGF, bFGF, MCP1 and endothelial cell proliferation marker CD31), resulting in hindered tumor growth [100].